Has introduction of azacytidine in everyday clinical practice improved survival in late-stage Myelodysplastic syndrome? A single center experience

详细信息    查看全文

• 作者：Menelaos Papoutselis ; Evdoxia Douvali ; Vasileios Papadopoulos ; Emmanouil Spanoudakis ; Dimitrios Margaritis ; Costas Tsatalas ; Ioannis Kotsianidis
• 关键词：Azacytidine ; MDS ; AML ; Response
• 刊名：Leukemia Research
• 出版年：February, 2014
• 年：2014
• 卷：38
• 期：2
• 页码：161-165
• 全文大小：919 K

文摘

Data derived from clinical trials consistently show a prolongation of overall survival of late-stage MDS patients with the introduction of azacytidine. Nevertheless, the applicability of the above results to real-world clinical settings may be questionable due to the strict design, the controlled medical environment, and the limited patient sample of explanatory studies. We retrospectively compared the outcome of two well-balanced groups of late-stage MDS patients. The first consisted of 46 patients treated with azacytidine (AZA cohort) and the second of 41 patients treated with other agents (non-AZA cohort). Patients in the AZA cohort displayed superior survival compared to the non-AZA ones. However, subgroup analysis revealed that azacytidine conferred a significant survival advantage only in patients with AML-MDS and those who attained a CR at any time after treatment initiation, while all other patients displayed comparable outcome with the non-AZA cohort. Larger series are needed to determine which patients benefit most from azacytidine therapy.